Open AccessProstate Cancer Screening, Diagnostic, Treatment Procedures and Costs in Sub-Saharan Africa: A Situational Analysis
Author(s) -
Louise Kathini Makau-Barasa,
Achille Manirakiza,
André Lopes Carvalho,
Timothy R. Rebbeck
Publication year - 2022
Publication title -
cancer control
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.794
H-Index - 72
eISSN - 1526-2359
pISSN - 1073-2748
DOI - 10.1177/10732748221084932
Subject(s) - medicine , overdiagnosis , prostate cancer , prostate cancer screening , rectal examination , cancer , gynecology , population , prostate , prostate specific antigen , health care , brachytherapy , intensive care medicine , oncology , radiation therapy , environmental health , economics , economic growth
Purpose Prostate cancer mortality is predicted to nearly double by 2040 in Sub-Saharan Africa (SSA). The lack of prostate cancer screening in SSA contributes to late-stage diagnosis, treatment delays, and poor survival among patients. We analyzed the availability and use of prostate cancer screening, diagnostic and treatment guidelines, procedures, and costs in few SSA countries to determine factors for consideration in the development of prostate cancer screening guidelines for SSA.Methods We applied mixed methods approaches to collect data through an electronic survey administered to clinicians (oncologists, urologists, pathologists, nurses, and radiation oncologists) providing prostate cancer screening, diagnosis, and treatment services in multiple sub-Saharan countries.Results Inconsistencies in respondents’ understanding of the availability and use of prostate cancer screening guidelines in their countries were noted. Prostate Specific Antigen (PSA) and Digital Rectal Examination (DRE) were the most commonly available screening modalities. Available diagnostic procedures included a combination of prostate biopsies, transrectal ultrasonography, and DRE. Our study’s data suggest that PSA and DRE exams are available for early diagnosis and screening procedures. Availability of treatment modalities with curative intent and costs for prostate cancer related procedures varied between and within countries.Conclusions PSA and DRE are available for detecting prostate cancer and may detect aggressive cancers early, leading to improved outcomes. However, PSA screening is also associated with overdiagnosis and over-treatment. National prostate cancer policies should consider health systems, evidence-based guidelines, population characteristics and healthcare financing to ensure access to clinically relevant and safe prostate cancer related care.